Summit Therapeutics (SMMT) Accumulated Depreciation & Amortization (2019 - 2024)
Historic Accumulated Depreciation & Amortization for Summit Therapeutics (SMMT) over the last 6 years, with Q4 2024 value amounting to $1.1 million.
- Summit Therapeutics' Accumulated Depreciation & Amortization rose 729.37% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year increase of 729.37%. This contributed to the annual value of $1.1 million for FY2024, which is 729.37% up from last year.
- Latest data reveals that Summit Therapeutics reported Accumulated Depreciation & Amortization of $1.1 million as of Q4 2024, which was up 729.37% from $1.0 million recorded in Q4 2023.
- In the past 5 years, Summit Therapeutics' Accumulated Depreciation & Amortization registered a high of $1.3 million during Q4 2022, and its lowest value of $1.0 million during Q4 2021.
- In the last 5 years, Summit Therapeutics' Accumulated Depreciation & Amortization had a median value of $1.1 million in 2024 and averaged $1.1 million.
- Per our database at Business Quant, Summit Therapeutics' Accumulated Depreciation & Amortization soared by 261661.56% in 2020 and then crashed by 1966.08% in 2023.
- Quarter analysis of 5 years shows Summit Therapeutics' Accumulated Depreciation & Amortization stood at $1.1 million in 2020, then decreased by 8.24% to $1.0 million in 2021, then grew by 25.19% to $1.3 million in 2022, then decreased by 19.66% to $1.0 million in 2023, then grew by 7.29% to $1.1 million in 2024.
- Its Accumulated Depreciation & Amortization was $1.1 million in Q4 2024, compared to $1.0 million in Q4 2023 and $1.3 million in Q4 2022.